Effects of smoking on the pharmacokinetics and pharmacodynamics of a nicotine patch

Biopharmaceutics and Drug Disposition

Volumn 29, Issue 9, 2008, Pages 521-528

  Yun, Hwi Yeol ^a   Seo, Jeong Won ^b   Choi, Ji Eun ^c   Baek, In Hwan ^b   Kang, Wonku ^d   Kwon, Kwang Il ^b  

^a Choongwae Pharma Co   (South Korea)

^b Chungnam National University   (South Korea)

^c Yuhan Corporation   (South Korea)

^d Catholic University of Daegu   (South Korea)

Author keywords

Cotinine; Nicotine; Patch; Pharmacodynamics; Pharmacokinetics

Indexed keywords

NICOTINE PATCH; NICOTINELL TTS20; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG METABOLISM; DRUG WITHDRAWAL; FEMALE; HEART RATE; HEMODYNAMICS; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NAUSEA; PARALLEL DESIGN; PHARMACODYNAMICS; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSDERMAL PATCH; VOMITING;

ADMINISTRATION, CUTANEOUS; ADULT; AREA UNDER CURVE; BLOOD PRESSURE; COTININE; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HEART RATE; HUMANS; MALE; NICOTINE; NICOTINIC AGONISTS; SMOKING; YOUNG ADULT;

EID: 59849106822     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.637     Document Type: Article

References (34)

1. Fielding JE. Smoking: health effects and control. N Engl J Med 1985; 313: 491-498.
2. Molander L, Hansson A, Lunell E. Pharmacokinetics of nicotine in healthy elderly people. Clin Pharmacol Ther 2001; 69: 57-65.
3. Gore AV, Chien YW. The nicotine transdermal system. Clin Dermatol 1998; 16: 599-615.
4. Teneggi V, Squassante L, Iavarone L, Milleri S, Bye A, Gomeni R. Correlation and predictive performance of saliva and plasma nicotine concentration on tobacco withdrawal-induced craving. Br J Clin Pharmacol 2002; 54: 407-414.
5. Gomeni R, Teneggi V, Iavarone L, Squassante L, Bye A. Population pharmacokinetic-pharmacodynamic model of craving in an enforced smoking cessation population: indirect response and probabilistic modeling. Pharm Res 2001; 18: 537-543.
6. Fant RV, Henningfield JE, Shiffman S, Strahs KR, Reitberg DP. A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches. Pharmacol Biochem Behav 2000; 67: 479-482.
7. Hughes JR, Miller SA. Nicotine gums to help stop smoking. J Am Med Assoc 1984; 252: 2855-2858.
8. Mutalik S, Udupa N. Glibenclamide transdermal patches: physicochemical, pharmacodynamic, and pharmacokinetic evaluations. J Pharm Sci 2004; 93: 1577-1594.
9. Gorsline J, Gupta SK, Dye D, Rolf CN. Steady-state pharmacokinetics and dose relationship of nicotine delivered from Nicoderm® (Nicotine transdermal systems). J Clin Pharmacol 1993; 33: 161-168.
10. Bannon YB, Corish J, Corrigan OI, Devane JG, Kavanagh M, Mulligan S. Transdermal delivery of nicotine in normal human volunteers: a single dose and multiple dose study. Eur J Clin Pharmacol 1989; 37: 285-290.
11. Yun HY, Lee EJ, Chung SY, et al. The effects of food on the bioavailability of fenofibrate administered orally in healthy volunteers via sustained-release capsule. Clin Pharmacokinet 2006; 45: 425-432.
12. Allan SX, Lana LP, James AH, et al. Determination of nicotine and cotinine in human plasma by liquid-chromatography-tandem mass spectrometry with atmospheric-pressure chemical ionization interface. J Chromatogr B 1996; 682: 249-257.
13. Minister of Health. Guidance for Industry: Conduct and Analysis of Bioavailability and Bioequivalence Studies-Part B: Oral Modified Release Formulations. Health Canada: Ontario, 1996; 52-73.
14. Gupta SK, Benowitz NL, Jacob 3rd P, Rolf CN, Gorsline J. Bioavailability and absorption kinetics of nicotine following application of a transdermal system. Br J Clin Pharmacol 1993; 36: 221-227.
15. Benowitz NL, Perez-Stable EJ, Herrera B, Jacob 3rd J. Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. J Natl Cancer Inst 2002; 94: 108-115.
16. Dempsey D, Jacob 3rd P, Benowitz NL. Accelerated metabolism of nicotine and cotinine in pregnant smokers. J Pharmacol Exp Ther 2002; 301: 594-598.
17. Benowitz NL, Jacob 3rd P, Fong I, Gupta S. Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther 1994; 268: 296-303.
18. Tutka P, Mosiewicz J, Wielosz M. Pharmacokinetics and metabolism of nicotine. Pharmacol Rep 2005; 57: 143-153.
19. Hukkanen J, Jacob 3rd P, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005; 57: 79-115.
20. Tricker AR. Nicotine metabolism, human drug metabolism polymorphisms, and smoking behavior. Toxicology 2003; 183: 151-173.
21. Mwenifumbo JC, Sellers EM, Tyndale RF. Nicotine metabolism and CYP2A6 activity in a population of black African descent: impact of gender and light smoking. Drug Alcohol Depen 2007; 89: 24-33.
22. Benowitz NL, Perez-Stable EJ, Fong I, et al. Ethnic differences in N-glucuronidation of nicotine and cotinine. J Pharmacol Exp Ther 1999; 291: 1196-1203.
23. Schoedel KA, Sellers EM, Palmour R, et al. Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkey after long-term nicotine administration. Mol Pharmacol 2003; 62: 1025-1036.
24. Dueckershoff K, Unger, Frank A, Gillan EM, Guengerich FP, Warzecha H. Modified nicotine metabolism in transgenic tobacco plants expressing the human cytochrome P450 2A6 cDNA. FEBS Lett 2005; 579: 2480-2484.
25. Kyerematen GA, Damiano MD, Dvorchik BH, Vesell ES. Smoking-induced changes in nicotine disposition: application of new HPLC assay for nicotine and its metabolites. Clin Pharmacol Ther 1982; 32: 769-780.
26. Kyerematen GA, Morgan ML, Chattopadhyay B, deBethizy JD, Vesell ES. Disposition of nicotine and eight metabolites in smokers and nonsmokers: identification in smokers of two metabolites that are longer lived than cotinine. Clin Pharmacol Ther 1990; 48: 641-651.
27. Benowitz NL, Jacob 3rd P. Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers. Clin Pharmacol Ther 1993; 53: 316-323.
28. Benowitz NL, Jacob 3rd P. Effect of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism. Clin Pharmacol Ther 2000; 67: 653-659.
29. Novartis website. http://novartis.m114.co.kr/products/ products-view.asp?Istpe=&Seq=95 [1999]
30. Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol 1997; 29: 1422-1431.
31. Benowitz NL, Fitzgerald GA, Wilson M, et al. Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking. J Am Coll Cardiol 1993; 2: 1159-1167.
32. Benowitz NL, Porchet H, Sheiner L, Jacob 3rd P. Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin Pharmacol Ther 1988; 44: 23-28.
33. Benowitz NL, Jacob 3rd P, Jones RT, Rosenberg J. Inter-individual variability in the metabolism and cardiovascular effects of nicotine in man. J Pharmacol Exp Ther 1982; 221: 368-372.
34. Palmer KJ, Buckley MM, Faulds D. Transdermal nicotine, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an aid to smoking cessation. Drugs 1992; 44: 498-529.